Klinikum Stuttgart - Olgahospital, Stuttgart Cancer Centre, Paediatrics 5 (Oncology, Haematology, Immunology), Stuttgart, Germany.
Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
Cancer Med. 2023 Sep;12(17):18219-18234. doi: 10.1002/cam4.6409. Epub 2023 Aug 7.
To evaluate patient and tumour characteristics, treatment and their impact on survival in patients with a solitary pulmonary metastasis at first relapse of high-grade osteosarcoma.
Two-hundred and nineteen consecutive patients who had achieved a complete surgical remission and then developed a solitary pulmonary metastasis at first recurrence of high-grade osteosarcoma were retrospectively reviewed.
Two hundred and three (94.9%) of 214 patients achieved a second complete remission. After a median time from initial diagnosis of osteosarcoma to first relapse of 2.3 years (range, 0.3-18.8 years), actuarial post-relapse overall survival after 2 and 5 years was 72.0% and 51.2%. Post-relapse event-free survival was 39.1% and 31.1%. Median follow-up time was 3.2 years (range, 0.1-29.4 years). A longer time until first relapse and diagnosis due to imaging were positive prognostic factors in uni- and multivariate analyses, as were a second complete surgical remission and, in regard to death, the absence of a subsequent relapse. The use of salvage chemotherapy and radiotherapy were not associated with patient outcomes, nor was the surgical approach (thoracoscopy vs. thoracotomy) nor the exploration (uni- vs. bilateral).
Approximately half of the patients who experience a solitary pulmonary relapse at first recurrence of osteosarcoma remain alive 5 years after this first relapse. Only one third will remain disease-free. A complete surgical resection of the lesion is essential for long-term survival while relapse chemotherapy does not seem to improve survival. Innovative therapies are required to improve outcomes.
评估首次复发的高级别骨肉瘤患者的单一肺转移瘤的患者和肿瘤特征、治疗方法及其对生存的影响。
回顾性分析了 219 例连续患者,这些患者在完全手术缓解后首次复发高级别骨肉瘤时出现了单一性肺转移。
214 例患者中的 203 例(94.9%)获得了第二次完全缓解。从骨肉瘤初始诊断到首次复发的中位时间为 2.3 年(范围,0.3-18.8 年),2 年和 5 年后的复发后总体生存率分别为 72.0%和 51.2%。复发后无事件生存率分别为 39.1%和 31.1%。中位随访时间为 3.2 年(范围,0.1-29.4 年)。在单变量和多变量分析中,首次复发和因影像学检查而确诊的时间延长、第二次完全手术缓解以及死亡时无后续复发,均为预后良好的因素。挽救性化疗和放疗与患者结局无关,手术方式(胸腔镜与开胸术)或探查(单侧与双侧)也无关。
在首次复发的骨肉瘤患者中,约一半经历单一性肺转移瘤的患者在首次复发后 5 年仍存活。只有三分之一的患者将保持无疾病状态。对病变进行完全手术切除对于长期生存至关重要,而复发时的化疗似乎并不能提高生存率。需要创新疗法来改善治疗效果。